Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Mayerhöfer ME, Poulain S, Tournilhac O, Pemovska T, Chong SJF, Van der Kouwe E, Kazianka L, Hopfinger G, Heintel D, Jäger R, Raderer M, Jäger U, Simonitsch-Klupp I, Sperr WR, Kubicek S, Davids MS, Staber PB.
Kornauth C, et al. Among authors: guillemette c.
Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304.
Haematologica. 2021.
PMID: 33626863
Free PMC article.
No abstract available.